Injective
Why Injective is up 1.1% in the last hour
Analysis
Injective (INJ) rose 1.1% over the past hour, likely supported by bullish sentiment after Injective CEO Eric Chen said he expects US INJ ETFs to launch sooner than 2027. The ETF-related optimism can boost near-term demand as traders anticipate broader access and potential inflows tied to an ETF product.
Contributing Factors (1)
Injective CEO Eric Chen expects US INJ ETFs to launch sooner than 2027
There are currently two ETF applications tied to INJ — the 21Shares Injective ETF and the Canary Staked INJ ETF.
Move Details
Explanation Confidence
High confidence in the explanation based on source reliability and timing.